文献速递心脏核医学

99mTc-3SPboroxime:一种心肌摄取高、心肌滞留时间长的中性99mTc(III)放射性示踪剂

99mTc-3SPboroxime: A neutral 99mTc(III) radiotracer with high heart uptake and long myocardial retention.
PubMed 文献 · J Nucl Cardiol · 2020-03-16

在正常猪和急性心肌梗死猪模型中,99mTc-3SPboroxime的初始心肌摄取接近99mTc-Teboroxime但高于99mTc-Sestamibi,心肌滞留时间长于99mTc-Teboroxime,注射后13-15分钟心/肝比值高于99mTc-Teboroxime,K1值高于99mTc-Sestamibi,K2值在静息和双嘧达莫负荷下均低于99mTc-Teboroxime,注射后15分钟内任意5分钟窗口均可获得高质量SPECT图像。

要点

  • 正常猪和急性心肌梗死猪模型中,99mTc-3SPboroxime注射后15分钟内任意5分钟窗口均可获得高质量SPECT图像。
  • 99mTc-3SPboroxime的心/肝比值在注射后13-15分钟高于99mTc-Teboroxime。
  • 99mTc-3SPboroxime的K1值高于99mTc-Sestamibi,K2值在静息和负荷下均低于99mTc-Teboroxime。

核心结论

  • 99mTc-3SPboroxime因其心肌摄取、心/肝比值和SPECT图像质量,以及在评估负荷血流方面优于99mTc-Sestamibi,是一种有前景、有望未来临床转化的放射性示踪剂。

研究设计与样本

  • 在正常猪(含或不含双嘧达莫,n=9)和急性心肌梗死猪(n=3)中,与99mTc-Teboroxime和99mTc-Sestamibi对照,进行99mTc-3SPboroxime动态SPECT研究。
  • 注射后立即开始列表模式采集并持续15分钟,勾画心脏(梗死区和远程区)及肝脏感兴趣区生成时间-活性曲线,计算心/肝和梗死/远程放射性比值,采用单组织室模型获得K1和K2值。

主要发现

  • 99mTc-3SPboroxime的初始心肌摄取接近99mTc-Teboroxime但高于99mTc-Sestamibi,心肌滞留时间长于99mTc-Teboroxime。
  • 注射后13-15分钟,99mTc-3SPboroxime的心/肝比值高于99mTc-Teboroxime。
  • 静息K1:99mTc-3SPboroxime 0.63 ± 0.11 vs 99mTc-Sestamibi 0.40 ± 0.04 mL·min-1·g-1,P=0.027;负荷K1:0.89 ± 0.05 vs 0.54 ± 0.08 mL·min-1·g-1,P=0.031。
  • 静息K2:99mTc-3SPboroxime 0.22 ± 0.04 vs 99mTc-Teboroxime 0.33 ± 0.11 mL·min-1·g-1,P=0.003;负荷K2:0.31 ± 0.03 vs 0.60 ± 0.30 mL·min-1·g-1,P=0.047。
  • 正常猪和急性心肌梗死猪模型中,注射99mTc-3SPboroxime后15分钟内任意5分钟窗口均可获得高质量SPECT图像,急性心肌梗死猪心尖部和前壁灌注缺损清晰可见。

关键数值与推荐

  • 99mTc-3SPboroxime的静息K1为0.63 ± 0.11 mL·min-1·g-1,高于99mTc-Sestamibi的0.40 ± 0.04 mL·min-1·g-1(P=0.027)。
  • 99mTc-3SPboroxime的负荷K1为0.89 ± 0.05 mL·min-1·g-1,高于99mTc-Sestamibi的0.54 ± 0.08 mL·min-1·g-1(P=0.031)。
  • 99mTc-3SPboroxime的静息K2为0.22 ± 0.04 mL·min-1·g-1,低于99mTc-Teboroxime的0.33 ± 0.11 mL·min-1·g-1(P=0.003)。
  • 99mTc-3SPboroxime的负荷K2为0.31 ± 0.03 mL·min-1·g-1,低于99mTc-Teboroxime的0.60 ± 0.30 mL·min-1·g-1(P=0.047)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 99mTc-3SPboroxime is a 99mTc(III) complex with high initial heart uptake comparable to that of 99mTc-Teboroxime, but with significantly longer myocardial retention in Sprague-Dawley rats. This study was performed to demonstrate its feasibility on myocardial perfusion imaging and myocardial blood flow quantification in swine models. METHODS: Dynamic single-photon emission computed tomography (SPECT) studies with 99mTc-3SPboroxime were performed in normal (with/without dipyridamole, n = 9) and acute myocardial infarction (AMI) swine (n = 3) in comparison with 99mTc-Teboroxime and 99mTc-Sestamibi. List-mode acquisitions were immediately started after injection and continued for 15 minutes. Regions of interest were drawn on heart (infarct and remote areas of AMI swine) and liver to generate time activity curves. Heart/liver and infarct/remote radioactivity ratios were calculated. One-tissue compartment model was implemented to obtain K1 and K2 values. RESULTS: The initial heart uptake of 99mTc-3SPboroxime was close to that of 99mTc-Teboroxime, but higher than that of 99mTc-Sestamibi. 99mTc-3SPboroxime had a myocardial retention longer than that of 99mTc-Teboroxime. The heart/liver ratio of 99mTc-3SPboroxime was higher than that of 99mTc-Teboroxime at later stage (13-15 minutes post-injection). The K1 value of 99mTc-3SPboroxime was much higher than that of 99mTc-Sestamibi, and the K2 value was significantly lower than that of 99mTc-Teboroxime both at rest and dipyridamole stress (rest K1: 0.63 ± 0.11 vs 0.40 ± 0.04 mL·min-1·g-1, P = 0.027; stress K1: 0.89 ± 0.05 vs 0.54 ± 0.08 mL·min-1·g-1, P = 0.031; rest K2: 0.22 ± 0.04 vs 0.33 ± 0.11 mL·min-1·g-1, P = 0.003; stress K2: 0.31 ± 0.03 vs 0.60 ± 0.30 mL·min-1·g-1, P = 0.047). High quality SPECT images could be obtained in any of the 5 minutes windows over the first 15 minutes after injection of 99mTc-3SPboroxime in normal and AMI swine models. Apical and anterior perfusion defects were clearly visualized in AMI swine. CONCLUSION: 99mTc-3SPboroxime is a promising radiotracer for future clinical translation considering its heart uptake, heart/liver ratio and SPECT image quality, as well as the advantage over 99mTc-Sestamibi in the definition of stress flow.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Xi XY, Wang L, Hsu B, et al. 99mTc-3SPboroxime: A neutral 99mTc(III) radiotracer with high heart uptake and long myocardial retention. J Nucl Cardiol. 2020. PMID: 32180138. doi:10.1007/s12350-020-02087-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。